ArticleKidney medicine2025
Inpatient Utilization of Therapeutic Plasma Exchange in the United States: 2016-2021.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Specialist Distribution and Regional Variation in Plasmapheresis Use in Japan: A Population-Level Cross-Sectional Study.Journal of clinical apheresis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Therapeutic plasma exchange (TPE) is used in a variety of autoimmune, inflammatory, hematological, and metabolic disorders. We described the contemporary scope of inpatient utilization of TPE in the United States. Study Design: A cross-sectional study. Setting & Participants: The national inpatient sample dataset from year of 2016 to 2021. Exposures: Inpatient utilization of TPE. Outcomes: We described demographics, associated comorbid conditions, hospital characteristics, and hospital costs by comparing patients treated with those not treated by TPE. We reported the top 25 clinical conditions treated by TPE. We described the top 10 diseases or conditions for the first discharge diagnosis as acute kidney injury (AKI) (International Classification of Diseases, Tenth Revision code: N17.9) treated by TPE. Analytical Approach: All descriptive and multivariable analyses considered the complex survey design for every calendar year sampling of national inpatient sample; the results were weighted to reflect national estimates. Results: During 2016-2021, a total of 106,035 hospitalizations (∼0.051% of the total hospitalizations) were treated by TPE. The 5 most common conditions treated by TPE were myasthenia gravis with (acute) exacerbation (9.53%), Guillain-Barre syndrome (6.19%), thrombotic microangiopathy (6.18%), kidney transplant rejection (5.42%), and sepsis, unspecified organism (3.62%). AKI was the 13th most common condition, accounting for 1.82% of all cases treated by TPE, while the most common underlying condition for AKI was multiple myeloma (without achieving remission). The temporal trend of indications used by TPE in the US practice from 2016 to 2021 aligns well with the updated guideline by the American Society of Apheresis. The TPE utilization was associated with higher inpatient costs after accounting for length of stay; odds ratio ranges: 3.47 (2.99-4.03)-11.07 (10.19-12.03). Limitations: Lack of laboratory data. Conclusions: The TPE continues to be used to treat a variety of serious autoimmune and inflammatory diseases, in accordance with published clinical practice guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.